Novartis' asthma drug fails in phase 3, raising doubts about Gossamer's prospects

Novartis' asthma drug fails in phase 3, raising doubts about Gossamer's prospects

Source: 
Fierce Biotech
snippet: 

Novartis’ asthma prospect fevipiprant has failed to improve lung function in two phase 3 trials. The negative top-line data deal a big blow to the prospects of a drug analysts tipped to achieve blockbuster sales if it cleared phase 3.